You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Tegafur?

Tegafur is an investigational drug.

There have been 129 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Taiwan University Hospital, and Taiho Oncology, Inc.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Tegafur
TitleSponsorPhase
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic CancerLee's Pharmaceutical LimitedPhase 2
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Yu jirenPhase 2
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerACT GenomicsPhase 2

See all Tegafur clinical trials

Clinical Trial Summary for Tegafur

Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur

See all Tegafur clinical trials

US Patents for Tegafur

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Tegafur   Start Trial Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL)   Start Trial
Tegafur   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Tegafur   Start Trial Constructs containing multiple expression cassettes for cancer therapy Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Jerusalem, IL)   Start Trial
Tegafur   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur Canada CA2961033 2034-09-11   Start Trial
Tegafur European Patent Office EP3192791 2034-09-11   Start Trial
Tegafur Japan JPWO2016039408 2034-09-11   Start Trial
Tegafur World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11   Start Trial
Tegafur European Patent Office EP2134373 2027-02-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.